Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Share News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 49.05
Bid: 48.80
Ask: 48.95
Change: -0.50 (-1.01%)
Spread: 0.15 (0.307%)
Open: 49.30
High: 49.40
Low: 48.35
Prev. Close: 49.55
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IP Group net asset value falls, but losses narrow

Wed, 13th Mar 2024 07:22

(Sharecast News) - Intellectual property-focussed investor IP Group reported a net asset value of £1.19bn in its results for 2023 on Wednesady, or 114.3p per share, down from £1.38bn and 132.9p per share in 2022.

The FTSE 250 company said despite the decrease, the return on net asset value still improved to -13% from -20% year-on-year, while the loss for the year narrowed significantly to £174.4m from £344.5m.

Total portfolio value stood at £1.16bn, down from £1.26bn in the previous year, while gross cash and deposits increased to £336.9m from £241.5m.

The firm made portfolio investments of £73.2m in 33 companies across its three high-growth sectors, slightly lower than the £93.5m invested in 46 companies in 2022.

IP Group launched a £20m share buyback programme, and announced future cash returns in the form of share buybacks when the share price discount to net asset value exceeds 20%.

It said that over £75m in total cash had been returned to shareholders through dividends and share buybacks since 2021.

The company said its portfolio was maturing, with multiple near-term value creation opportunities.

Over 10 companies were now in clinical studies, with key data expected by the end of 2025.

Capital allocation remained focussed on high-growth sectors such as life sciences, deeptech, and cleantech.

The portfolio raised £0.7bn in total capital in 2023, with leading co-investors including Bosch Ventures, BP Ventures, Clean Energy Ventures, and others.

However, the firm said it had decided to deprioritise future investment in its US platform and cease plans for a China growth fund.

"The market environment for early-stage investing remained challenging in 2023," said chief executive officer Greg Smith.

"In response, we have prioritised and heavily focused our activities and capital on developing leading portfolio opportunities in the high-growth sectors where our teams have deep expertise.

"The group's portfolio successfully raised a total of £0.7bn, with the group investing £73m alongside more than fifty co-investors."

Smith said that, having appropriately managed its level of portfolio investment, the group finished the year in a strong financial position with £227m gross cash, describing that as "an important strategic asset" in the current environment.

"We have an excellent team that combines university relationships with deep sector experience and networks, allowing us to access highly differentiated dealflow," he said of IP Group's outlook.

"We are one of the companies most closely aligned with the UK's 'science superpower' ambition, which we intend to build on this year.

"In pursuing our purpose to accelerate the power of science for a better future by starting and growing businesses driving the energy transition, the digital transformation and improved health outcomes, we can make a significant dent in some of society's biggest needs and deliver compelling financial returns for our shareholders."

At 0815 GMT, shares in IP Group were down 1.03% at 51.07p.

Reporting by Josh White for Sharecast.com.

More News
5 Aug 2021 08:49

IP Group launches share buyback as interim profits surge

(Sharecast News) - Intellectual property-based business developer IP Group said on Thursday that it will launch a £20.0m share buyback after witnessing a rise in interim profits.

Read more
29 Jul 2021 16:00

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
27 Jul 2021 12:07

IP Group's Artios raises USD153 million for cancer therapy pipeline

IP Group's Artios raises USD153 million for cancer therapy pipeline

Read more
27 Jul 2021 09:18

IP Group portfolio company completes Series C financing

(Sharecast News) - Intellectual property-based business investor IP Group said on Tuesday that portfolio company Artios Pharma had completed a $153.0m Series C financing to fund the further development of its clinical-stage pipeline.

Read more
28 Jun 2021 13:41

IN BRIEF: IP Group Non-Exec Director Hynes buys 21,000 shares

IN BRIEF: IP Group Non-Exec Director Hynes buys 21,000 shares

Read more
17 Jun 2021 09:48

IP Group investee Apollo Therapeutics completes USD145 million raise

IP Group investee Apollo Therapeutics completes USD145 million raise

Read more
17 Jun 2021 07:40

IP Group portfolio business raises $145m in financing round

(Sharecast News) - Intellectual property business IP Group said on Thursday that portfolio company Apollo Therapeutics had completed a $145.0m financing round.

Read more
9 Jun 2021 16:08

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
9 Jun 2021 14:27

IN BRIEF: IP Group invests GBP250,000 in GBP1.1 million Itaconix raise

IN BRIEF: IP Group invests GBP250,000 in GBP1.1 million Itaconix raise

Read more
9 Jun 2021 09:21

IN BRIEF: IP Group expects GBP80 million in first half realisations

IN BRIEF: IP Group expects GBP80 million in first half realisations

Read more
9 Jun 2021 08:01

IP Group preparing for first divi as portfolio progress continues

(Sharecast News) - Intellectual property business developer IP Group said on Wednesday that for the year to date, its positive progress made by many of its portfolio companies in 2020 had continued.

Read more
7 Jun 2021 09:24

IP Group sells part of Iksuda Therapeutics stake in financing round

IP Group sells part of Iksuda Therapeutics stake in financing round

Read more
7 Jun 2021 07:25

IP Group portfolio co Iksuda raises £42m to develop cancer drug

(Sharecast News) - Intellectual property business developer IP Group said its portfolio company Iksuda Therapeutics had completed a $42m (£29m) financing round to fund human clinical trials of its lead cancer drug.

Read more
2 Jun 2021 15:55

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
28 May 2021 15:12

IP Group launches joint venture aiming to provide capital in China

IP Group launches joint venture aiming to provide capital in China

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.